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ABSTRACT 
Peritoneal mesotheliomas are aggressive tumors arising from the 
peritoneal mesothelium. Tumor markers are biochemical substances 
produced by tumor cells due to the effect of  malignant process. 
They can be used for screening, diagnosis, and predicting the 
prognosis. β-human chorionic β-human chorionic gonadotrophin 
(β-hCG), is a marker of germ cell tumors and trophoblastic 
diseases. In some reports,  a relationship between β-hCG and 
other malignant diseases has been described. Hereby,  we present 
a case of malignant peritoneal mesothelioma associated with 
elevated serum β-hCG levels. A 49-year-old man was admitted to 
the hospital with ascites. Peritoneal mesothelioma was diagnosed 
with peritoneal biopsy. During the treatment period, serum β-hCG 
levels were elevated together with disease progression and tissue 
samples stained positive for β-hCG. Rising levels of serum β-hCG 
due to disease progression can predict the response to treatment. 
If these levels were elevated at the beginning of the treatment, it 
may be a prognostic marker for peritoneal mesothelioma. Thus, 
β-hCG may be an important marker for prognosis or prediction of 
treatment for peritoneal mesothelioma patients. 
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ÖZ 
Peritoneal mezotelyomalar, peritoneal mezotelyumdan köken alan 
agresif tümörlerdir. Tümör belirteçleri, malign olayların etkilerinden 
dolayı üretilen biyokimyasal maddelerdir. Kanser taramasında, 
tanısında, ya da kanser prognozunu belirlemek için kullanılabilir. 
β-human koryonik gonadotropin (β-hCG),  germ hücreli tümörler 
ve trofoblastik hastalıklarda kullanılan bir belirteçtir. Bazı 
yayınlarda yazarlar,  β-hCG’nin diğer malignitelerle de ilişkili 
olabileceğini belirtmişlerdir. Biz burada,  serum β-hCG yüksekliği 
ile seyreden malign peritoneal mezotelyomalı hastamızı sunduk. 
49 yaşında bir erkek hasta hastaneye assitle başvurdu. Peritoneal 
mezotelyoma tanısı periton biyopsisiyle kondu. Tedavisi devam 
ettiği sırada hastalık progresyonuyla birlikte serum β-hCG seviyesi 
yükseldi ve doku β-hCG ile pozitif olarak boyandı. Hastalık 
progresyonuyla artan serum β-hCG seviyeleri tedavi yanıtını 
predikte edebilir. Eğer peritoneal mezotelyomalı bir hastada serum 
β-hCG seviyesi tedavi başlangıcında yüksek olarak saptandıysa, 
prognostik bir belirteç olarak kullanılabilir. Tüm bunlardan dolayı, 
β-hCG’nin peritoneal mezotelyomalı hastalarda tedaviyi predikte 
edebilecek ve prognozu belirlemede yardımcı önemli bir belirteç 
olarak kullanılabileceğini  düşünüyoruz.
Anahtar kelimeler: Mezotelyoma, Human koryonik gonadotropin, 
Tümör belirteci
Introduction
Mesotheliomas are rare and aggressive tumors arising from 
the mesothelium which derive from the lining of the coelomic 
epithelium in the embryo, the embryonic mesoderm. The 
pleura is the most commonly involved site (65-70%), while 
the peritoneum (30%), testicular tunica vaginalis and the 
pericardium (1-2%) are other sites of origin [1]. 
Tumor markers are biochemical substances produced 
mostly by tumor cells. They can be used for screening a healthy 
or a high risk population for the presence of cancer, to support 
the diagnosis of an already diagnosed patient with a specific 
type of cancer or to determine prognosis of an asymptomatic 
patient receiving cancer treatment [2]. β-human chorionic 
gonadotropin (β–hCG) and human placental lactogen (hPL) are 
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the most common markers used for diagnosis and follow-up of 
germ cell tumors and trophoblastic diseases. In some studies, 
it was shown that β-hCG could also be used as a marker for 
tumors other than germ cell and trophoblastic origins. In a 
comprehensive review published in 1987, high β-hCG levels 
were detected in 20% of cancer patients whose tumors were not 
of trophoblastic or germ cell origin [3]. 
Malignant peritoneal mesotheliomas are aggressive 
tumors with no known tumor markers either for diagnosis 
or treatment. This case report presents a patient with 
malignant peritoneal mesothelioma who was admitted to 
our center with high serum β-hCG levels that increased with 
progression of the disease.
Case Report
A 49-year-old male patient was admitted with abdominal 
discomfort, pain and loss of appetite. His history was 
unremarkable. Physical examination of the abdomen 
revealed ascites and there were palpable masses in the 
abdomen. Except for an increase in blood urea nitrogen 
and creatinine, biochemical tests were normal. All tumor 
markers other than an incidentally detected increase in 
β-hCG (441mIU/ml) were within normal limits. Lactate 
dehydrogenase (LDH) and thyroid stimulating hormone 
(TSH) were also normal. His Eastern Cooperative Oncology 
Group performance status  (ECOG PS) was 1.
Scrotal ultrasound revealed normal findings, and chest 
computed tomography (CT) did not demonstrate any 
mediastinal pathology. Abdominal magnetic resonance 
(MRI) imaging showed ascites with two papillary and 
irregularly shaped mass lesions around the descending colon, 
6.5x3 cm and 3x3.5 cm in size. They appeared hypointense 
at T1W and hyperintense at T2W sequences. Diaphragmatic 
surfaces and paracolic areas also appeared to have some 
irregularities, probably due to minute lesions. Omental cake 
formation was also identified (Fig. 1). 
Fig. 1. Axial T2W MRI image of malignant peritoneal mesothelioma 
Peritoneal biopsy under ultrasound guidance was 
performed and identified the lesions as a biphasic, 
epithelioid and sarcomatoid malignant mesothelioma. 
There were loosely bound, atypical epithelioid cells which 
had large polygonal cytoplasms, oval-round shaped nuclei 
and remarkable nucleoli, as well as atypical mesenchymal 
cells, scarce cytoplasms and spindle-like nuclei. Epithelioid 
cells stained positive with CK5-6 (cytokeratin), epithelial 
membrane antigen (EMA) and calretinin and negative with 
P53 and desmin. Partial membraneous staining was observed 
with  Hector Battifora mesothelial cell antibody (HMBE-1) 
at the epithelioid side of the tumor. Both components of the 
tumor were stained positively with Wilm’s tumor 1( WT1), 
with the stain being more prevalent in the epithelioid parts. 
With these findings of deteriorating renal function 
and unfavorable ECOG PS, the patient was considered 
inoperable and chemotherapy with carboplatin AUC5, 
q21was considered. After the first cycle, the patient’s ECOG 
PS increase to 2, his ascites increased and chemotherapy 
was ceased. At this stage, β-hCG level was 3944mIU/
mL. Paraffin blocks were reconsidered for staining with 
β-hCG and human placental lactogen (hPL). Cytoplasms 
of the sarcomatoid components stained positive with β-hCG 
(Fig.  2) but there was no staining with hPL. The patient was 
deceased within five weeks of the diagnosis. 
Fig. 2. Immun-stains; hematoxylin-eosin (H&Ex20), H&Ex40, 
β-hCGx40, WT1x40, Calretinin x40). Cytoplasmic immune 
reactivity with beta human chorionic gonadotropin (β-hCG) of 
peritoneal mesothelioma (magnification X4).
Hematoxylin-eosin x20
Calretinin x40
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Discussion
Peritoneal mesothelioma is a rare tumor characterized by 
diffuse or locoregional involvement of peritoneal surfaces. 
In industrialized countries, the incidence is currently 
estimated to be between 0.5-3 cases per million for men, 
and 0.2-2 cases per million for women [4]. Currently, no 
biomarkers have been identified for use in the diagnosis 
and/or to follow-up of this entity. However, there are 
studies searching for a tumor marker, β-hCG in particular. 
In a study by Rich et al., high β-hCG levels were found 
in the ascitic fluid of malignant peritoneal mesothelioma 
patients, while their serum β-hCG levels were normal. It 
was hypothesized that β-hCG synthesized and secreted by 
the tumor cells into the ascites was rapidly cleared from the 
serum [5]. In another study, two patients with epithelioid 
pleural mesothelioma demonstrated elevated serum β-hCG 
levels and giant trophoblast-like cells in the tumor also 
stained positive for β-hCG. The authors suggested that 
this finding occurred as a result of ‘disdifferantiation’ of 
tumor cells into trophoblast-like cells [6]. Moreover, in their 
report concerning 201 cancer patients including four cases 
with malignant mesothelioma, Zimmerman et al., reported 
that serous effusions from two out of four mesothelioma 
patients (50%) and twenty-eight patients out of forty-four 
adenocarcinoma patients (64%) stained positive for hCG 
and mucin. They concluded that β-hCG was not clinically 
useful for effusion cytology because of a low specificity [7]. 
In another study by Ugurman et al., pleural and serum β-hCG 
levels and their ratio were evaluated for discriminating 
benign and malignant pleural effusions. Although there 
were no significant differences between benign and 
malignant groups in terms of β-hCG levels, the ratio of 
pleural fluid/serum β-hCG was significantly higher in the 
malignant compared to the benign group. Six mesothelioma 
patients of 27 cancer cases had the highest amount of fluid/
serum β-hCG ratio (325 mIU/L in mesotheliomas compared 
to 55 mIU/L in other cancers) [8]. In his study,  Gibbs et 
al., compared 29 mesotheliomas (12 epithelioid, 14 mixed 
epithelioid-sarcomatous, 3 sarcomatous) with 27 pulmonary 
adenocarcinomas and searched for immune staining with 
six different tumor markers including β-hCG and hPL in 
formalin-fixed pathology specimens. Only one out of 27 
pulmonary mesotheliomas stained positive with β-hCG, but 
none with hPL. No information about the staining pattern in 
mesotheliomas was provided in this study  [9].
Our patient had high serum β-hCG levels at presentation 
and his levels increased with disease progression. Biopsy 
specimen from the sarcomatous component with a spindle-
like cytoplasm of the tumor also stained positive with 
β-hCG. Our patient was the first case with all of these 
findings (Table I). 
Author
Number 
of cases
Mesothelioma type Serum β-hCG levels Tissue staining
Fluid βhCG 
levels
Pleural Peritoneal Presentation
Disease 
progression
β-hCG α-hCG hPL
 Rich, et al. [5] 1 _ 1 <1µg/ml _ _ _ _ +
Okamoto, et 
al. [6]
2
Epithelial _ _ >9000IU/L
(+)
cytoplasmic
(+)
Cytoplasmic
(+)cytoplasmic _
Epithelial _ 22.670IU/L
7220IU/L
with 
chemotherapy
(+)diffuse 
staining at giant 
cells
(+)diffuse 
staining at giant 
cells
(+)diffuse 
staining at giant 
cells
_
 Zimmerman, 
et al. [7]
4 Pleural _ _ _ _ _ _
(+) in 2 
patients
(% 50 
positive)
Ugurman, et 
al. [8]
6 Pleural _
55.67±132.84
(mean)
_ _ _ _ 325±3.8
 Gibbs,  et al. 
[9]
29
12 purely 
epithelial
14 mixed
Epithelial and 
sarcomatoid
3 purely 
sarcomatoid
_ _ _ 26/1+ _ 27/0 _
This study 1 _
Peritoneal mixed 
epitheliod and 
sarcomatoid
441mIU/mL
3944.55mIU/
mL
+ Unknown _ _
Table I. Immune-staining and laboratory features of patients from various studies.
β-hCG (beta-human chorionic gonadotropin), α-hCG (alpha-human chorionic gonadotropin), hPL (human placental lactogen), IU/L (international unit per liter)
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The increase in serum β-hCG levels (from 441 to 3944 
mU/mL) during disease progression could be a predictor 
for treatment response and/or a prognostic marker for 
mesothelioma since the marker was high also at presentation. 
High β-hCG levels were found to be correlated with a poor 
prognosis of the disease [10]. Okamoto et al.,  observed a 
decrease in β-hCG levels after chemotherapy [6]. 
We hypothesize that mesothelioma cells differentiate 
into cells which secrete β-hCG or β-hCG-like glycoproteins. 
There are some studies concerning mesothelial cell 
differentiation, in support for our hypothesis. In one of these 
studies, mesothelial cells were observed to have a pluripotent 
stem cell-like feature with the capacity to differentiate 
into cells of different phenotypes, and progenitor-like 
mesothelial cell lineages were also demonstrated. As an 
example, mesothelial cells were shown to express increasing 
levels of alkaline phosphatase and form bone-like nodules 
[9]. In our case, even though the sarcomatoid component of 
the tumor did not contain choriocarcinoma cells, it stained 
positive for β-hCG. 
Conclusion
Considering that nontrophoblastic tumors might stain 
positive for β-hCG in up to 20% of the patients [[3], our 
case is the first case in whom serum β-hCG levels increased 
with disease progression and the peritoneal mesothelioma 
stained positive for β-hCG. This is possibly related to the 
sarcomatoid component of the tumor.
β-hCG may be a marker for treatment prediction, and 
disease prognosis for mesothelioma patients. The low 
correlation between serum/tissue β-hCG levels may be 
due to tumor subtype (epithelioid or sarcomatoid), transfer 
problems from tissue to blood (endothelial barrier or 
clearance before transfer to blood), or destruction at blood. 
As a result, it is clear that more studies are required to 
determine the relation between β-hCG and mesothelioma. 
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